BIIB
Biogen Inc. Common Stock
Nasdaq · usd
Biogen Inc. Common Stock (BIIB) trades at $252.28 (-0.61%) as of 9:13:20 AM EDT on Oct 23, 2026, +11.56% over the past month. Market cap is $37.51B, with 4.9 days to cover in short interest.
Stock performance
How Biogen Inc. Common Stock (BIIB) stock has performed from one day to one year, with its 52-week range.
- 1D
- +5.34%
- 1W
- +7.86%
- 1M
- +11.56%
- YTD
- +44.24%
- 1Y
- +69.35%
- 52-wk range
- $138.00 – $254.41
Key statistics
Today's trading snapshot for BIIB: day range, open, previous close, volume and market cap.
- Day range
- $240.02 – $254.41
- Open
- $240.61
- Prev close
- $253.84
- Volume
- 2.24M
- Market cap
- $37.51B
- Shares out
- 147.75M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Biogen Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- 44.94
- P/S
- 3.74
- P/B
- 1.99
- P/FCF
- 13.91
- ROE
- 4.4%
- ROA
- 2.6%
- Debt/Equity
- 0.43
- Div yield
- 0.00%
As of Oct 22, 2026
8-K filings
Material corporate events Biogen Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Shareholder meetingsJun 10, 2026
On June 9, 2026, Biogen Inc. (the "Company") held its 2026 Annual Meeting of Stockholders. The final voting results for this meeting are as follows: Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of stockholders.
- Debt activityMay 14, 2026
On May 13, 2026, in connection with the completion of the Offer and the Merger, Biogen borrowed the full amount available under the Credit Agreement. The proceeds from the borrowings under the Term Facilities were used to pay a portion of the consideration for the Offer and the Merger and for other purposes in connection with the Transactions.
- Earnings and performanceApr 6, 2026
Results for the quarter ended March 31, 2026, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein.
- Investor communicationsMar 31, 2026
On March 31, 2026, Biogen held an investor webcast presentation announcing the Merger. A copy of the investor webcast presentation relating to the Merger is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
- Executive leadershipMar 11, 2026
Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026. The Company has initiated a search to identify the Company's next Chief Legal Officer.
BIIB short interest
How heavily BIIB is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.9
- Short interest
- 5.97M
- Avg volume
- 1.23M
As of · reported to FINRA twice monthly.
BIIB news
The latest news and headlines about Biogen Inc. Common Stock (BIIB).
- Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsightpositiveGlobeNewswire Inc.· Oct 22, 2026
- Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleasepositiveZacks Investment Research· Oct 22, 2026
- Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleasepositiveZacks Investment Research· Oct 21, 2026
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowpositiveZacks Investment Research· Oct 20, 2026
- AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 ResultspositiveZacks Investment Research· Oct 19, 2026
Frequently asked questions
What is the Biogen Inc. Common Stock (BIIB) stock price today?
Biogen Inc. Common Stock (BIIB) is trading at $252.28 (-0.61% on the day) as of 9:13:20 AM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Biogen Inc. Common Stock?
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025.
What is the short interest in BIIB?
As of Sep 30, 2026, BIIB has 5.97M shares short and 4.9 days to cover.
What exchange is BIIB listed on?
Biogen Inc. Common Stock (BIIB) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of BIIB with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BIIB analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.